Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Table 1

Baseline characteristics of retinopathy of prematurity infants receiving intravitreal conbercept or ranibizumab.

	Intravitreal conbercept	Intravitreal ranibizumab
No. of eyes (infants)	29 (15)	25 (13)	—
Mean GA (weeks)	28.96 ± 2.36 (26.14–33.43)	28.76 ± 2.25 (25.43–33.43)	0.817
Mean BW (g)	1168.8 ± 344.5 (850–2100)	1255.0 ± 356.9 (760–1950)	0.522
Male sex (%)	60%	61.54%	0.934
Mean PMA at first treatment	41.22 ± 4.39 (36.29–50.14)	39.42 ± 2.77 (36.00–44.86)	0.075
Mean injection times	1.28 ± 0.45 (1–2)	1.56 ± 0.65 (1–3)	0.074
Mean PMA at FA (weeks)	88.66 ± 10.88 (71.29–115.43)	98.02 ± 25.28 (65.57–133.71)	0.251

GA, gestational age; BW, birth weight; PMA, postmenstrual age; FA: fluorescein angiography. Data are mean ± SD(range).